Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julie Fox

Showing results (131-140 of 182) with videos related to

Pageof 19
Sort By:
HIV Medicine|January 12, 2024
Clinical epidemiology of COVID-19 in people of black ethnicity living with HIV in the UKZoe Ottaway, Lucy Campbell, Laura R Cechin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2018
Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment TrialAlejandro Arenas-Pinto, Birgit Grund, Shweta Sharma, et al.
Plos One|October 9, 2023
Preferences for oral PrEP dosing among adolescent boys and young men in three sub-Saharan African countriesAyoub Kakande, Andrew Sentoogo Ssemata, Richard Muhumuza, et al.
Frontiers in Immunology|June 21, 2021
Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral TherapyGenevieve E Martin, Debattama R Sen, Matthew Pace, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
HIV Medicine|January 29, 2026
Screening for Trypanosoma cruzi infection (Chagas disease) in the Latin American population living with HIV in LondonNatalie Elkheir, Shivani Singh, Birgit Barbini, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Cell Reports|April 27, 2022
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variantsJeffrey Seow, Carl Graham, Sadie R Hallett, et al.
BMC Infectious Diseases|May 16, 2022
Symptoms of post-traumatic stress and associations with sexual behaviour and PrEP preferences among young people in South Africa, Uganda and ZimbabweEmily L Webb, Janan J Dietrich, Andrew S Ssemata, et al.
Frontiers in Immunology|September 16, 2022
Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruptionMatthew Pace, Ane Ogbe, Jacob Hurst, et al.
Pageof 19

Showing results (131-140 of 182) with videos related to

Sort By:
Pageof 19
HIV Medicine|January 12, 2024
Clinical epidemiology of COVID-19 in people of black ethnicity living with HIV in the UKZoe Ottaway, Lucy Campbell, Laura R Cechin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2018
Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment TrialAlejandro Arenas-Pinto, Birgit Grund, Shweta Sharma, et al.
Plos One|October 9, 2023
Preferences for oral PrEP dosing among adolescent boys and young men in three sub-Saharan African countriesAyoub Kakande, Andrew Sentoogo Ssemata, Richard Muhumuza, et al.
Frontiers in Immunology|June 21, 2021
Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral TherapyGenevieve E Martin, Debattama R Sen, Matthew Pace, et al.
The Journal of Antimicrobial Chemotherapy|June 13, 2021
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIVAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
HIV Medicine|January 29, 2026
Screening for Trypanosoma cruzi infection (Chagas disease) in the Latin American population living with HIV in LondonNatalie Elkheir, Shivani Singh, Birgit Barbini, et al.
The Journal of Antimicrobial Chemotherapy|August 4, 2023
Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravirAna González-Cordón, Lambert Assoumou, Graeme Moyle, et al.
Cell Reports|April 27, 2022
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variantsJeffrey Seow, Carl Graham, Sadie R Hallett, et al.
BMC Infectious Diseases|May 16, 2022
Symptoms of post-traumatic stress and associations with sexual behaviour and PrEP preferences among young people in South Africa, Uganda and ZimbabweEmily L Webb, Janan J Dietrich, Andrew S Ssemata, et al.
Frontiers in Immunology|September 16, 2022
Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruptionMatthew Pace, Ane Ogbe, Jacob Hurst, et al.
Pageof 19